- Home
- PMVP vs VERU Comparison
PMVP vs VERU Comparison
Compare PMVP & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- VERU
- Stock Information
- Founded
- PMVP 2013
- VERU 1971
- Country
- PMVP United States
- VERU United States
- Employees
- PMVP N/A
- VERU N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- VERU Health Care
- Exchange
- PMVP Nasdaq
- VERU Nasdaq
- Market Cap
- PMVP 77.4M
- VERU 85.5M
- IPO Year
- PMVP 2020
- VERU 1990
- Fundamental
- Price
- PMVP $1.25
- VERU $3.55
- Analyst Decision
- PMVP Strong Buy
- VERU Strong Buy
- Analyst Count
- PMVP 1
- VERU 3
- Target Price
- PMVP $5.00
- VERU $33.33
- AVG Volume (30 Days)
- PMVP 2.7M
- VERU 120.2K
- Earning Date
- PMVP 11-06-2025
- VERU 08-12-2025
- Dividend Yield
- PMVP N/A
- VERU N/A
- EPS Growth
- PMVP N/A
- VERU N/A
- EPS
- PMVP N/A
- VERU N/A
- Revenue
- PMVP N/A
- VERU $16,886,419.00
- Revenue This Year
- PMVP N/A
- VERU N/A
- Revenue Next Year
- PMVP N/A
- VERU N/A
- P/E Ratio
- PMVP N/A
- VERU N/A
- Revenue Growth
- PMVP N/A
- VERU 337.24
- 52 Week Low
- PMVP $0.81
- VERU $2.64
- 52 Week High
- PMVP $1.84
- VERU $14.20
- Technical
- Relative Strength Index (RSI)
- PMVP 43.13
- VERU 46.07
- Support Level
- PMVP $1.12
- VERU $3.41
- Resistance Level
- PMVP $1.35
- VERU $3.68
- Average True Range (ATR)
- PMVP 0.16
- VERU 0.21
- MACD
- PMVP -0.03
- VERU 0.08
- Stochastic Oscillator
- PMVP 17.25
- VERU 43.25
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.